Drug Pipeline

TAS6417 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
1
Recruiting
2
Phase 3
2
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-05-22 NCT07601399 An EAP Treatment Protocol of Zipalertinib Available
Active Studies by Phase
Phase 3
2
Phase 2
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05973773 REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Active, Not Recruiting
NCT07128199 A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant… NSCLC, Stage IB-IIIA Active, Not Recruiting
Phase 2
NCT05967689 A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With… Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Recruiting
NCT07229339 Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage… Lung Non-Squamous Non-Small Cell Carcinoma Not Yet Recruiting
Sponsors Running TAS6417 Trials
Taiho Oncology, Inc. (3) Jonsson Comprehensive Cancer Center (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (1)
Get alerts when TAS6417 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free